Humacyte (HUMA)
NASDAQ:HUMA
Total Valuation
Humacyte has a market cap or net worth of $134.70M. The enterprise value is $109.46M.
Market Cap$134.70M
Enterprise Value$109.46M
Share Statistics
Humacyte has 222,019,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding222,019,100
Owned by Insiders11.39%
Owned by Institutions2.56%
Financial Efficiency
Humacyte’s return on equity (ROE) is -13.13 and return on invested capital (ROIC) is -106.99%.
Return on Equity (ROE)-13.13
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-106.99%
Return on Capital Employed (ROCE)-1.10
Revenue Per Employee9.35K
Profits Per Employee-187.31K
Employee Count218
Asset Turnover0.02
Inventory Turnover1.25
Valuation Ratios
The current PE Ratio of Humacyte is ―. Humacyte’s PEG ratio is 0.05.
PE Ratio―
PS Ratio74.54
PB Ratio48.86
Price to Fair Value48.86
Price to FCF-1.43
Price to Operating Cash Flow-0.91
PEG Ratio0.05
Income Statement
In the last 12 months, Humacyte had revenue of 2.04M and earned -40.83M in profits. Earnings per share was -0.26.
Revenue2.04M
Gross Profit-15.01M
Operating Income-107.44M
Pretax Income-40.83M
Net Income-40.83M
EBITDA-100.09M
Earnings Per Share (EPS)-0.26
Cash Flow
In the last 12 months, operating cash flow was -105.04M and capital expenditures -884.00K, giving a free cash flow of -105.93M billion.
Operating Cash Flow-105.04M
Free Cash Flow-105.93M
Free Cash Flow per Share-0.48
Dividends & Yields
Humacyte pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.75
52-Week Price Change-59.33%
50-Day Moving Average1.03
200-Day Moving Average1.53
Relative Strength Index (RSI)27.77
Average Volume (3m)7.58M
Important Dates
Humacyte upcoming earnings date is May 8, 2026, Before Open (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateMay 8, 2026
Ex-Dividend Date―
Financial Position
Humacyte as a current ratio of 3.69, with Debt / Equity ratio of 2085.75%
Current Ratio3.69
Quick Ratio2.95
Debt to Market Cap0.25
Net Debt to EBITDA-0.14
Interest Coverage Ratio-9.55
Taxes
In the past 12 months, Humacyte has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Humacyte EV to EBITDA ratio is -1.66, with an EV/FCF ratio of -1.57.
EV to Sales81.58
EV to EBITDA-1.66
EV to Free Cash Flow-1.57
EV to Operating Cash Flow-1.58
Balance Sheet
Humacyte has $50.50M in cash and marketable securities with $64.85M in debt, giving a net cash position of -$14.35M billion.
Cash & Marketable Securities$50.50M
Total Debt$64.85M
Net Cash-$14.35M
Net Cash Per Share-$0.06
Tangible Book Value Per Share$0.02
Margins
Gross margin is -736.46%, with operating margin of -5271.69%, and net profit margin of -2003.58%.
Gross Margin-736.46%
Operating Margin-5271.69%
Pretax Margin-2003.58%
Net Profit Margin-2003.58%
EBITDA Margin-4911.29%
EBIT Margin-5271.69%
Analyst Forecast
The average price target for Humacyte is $2.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$2.25
Price Target Upside294.74% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast82.23%